

13. Caryl C, Girard JP. The IL-1 like cytokine IL-33 is inactivated after maturation by caspase-1. *Proc Natl Acad Sci USA* 2009; 106: 9021–9026.
14. Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. *Cell Microbiol* 2006; 8: 1812–1825.
15. Shao W, Yeretssian G, Doiron K et al. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. *J Biol Chem* 2007; 282: 36321–36329.
16. Gurcel L, Abrami L, Girardin S, et al. Caspase-1 activation of lipid metabolic pathway in response to bacterial pore-forming toxins promotes cell survival. *Cell* 2006; 126: 1135–1145.
17. Bergsbaken T, et al. Pyroptosis: Host cell death and inflammation. *Nat Rev Microbiol* 2009; 7: 99–109.
18. Miao EA, et al. Caspase-1-induced pyroptosis in an innate immune effector mechanism against intracellular bacteria. *Nat Immunol* 2010; 11: 1136–1142.
19. Pétrilli V, Papin S, Dostert C, et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. *Nature* 2007; 14: 1583–1589.
20. Thomas PG, Dash P, Aldridge JR, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. *Immunity* 2009; 30: 566–575.
21. Duncan JA, Gao X, Huang MT, et al. *Neisseria gonorrhoeae* activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. *J Immunol* 2009; 182: 6460–6469.
22. Mariathasan S, Newton K, Monack D et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. *Nature* 2004; 430: 213–218.
23. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. *Nature* 2006; 440: 237–241.
24. Yazdi AS, Guarda G, Riteau N, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrps3) inflammasome and cause pulmonary inflammation through release of IL-1 α and IL-1 β . *Proc Natl Acad Sci USA* 2010; 107: 19449–19454.
25. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. *J Clin Invest* 2009; 119: 3502–3511.
26. Šedivá A, Horváth R, Maňásek V, et al. Cluster of patients with Familial Mediterranean fever and heterozygous carriers of mutations in MEFV gene in the Czech Republic. *Clin Genet* 2014; 86: 564–569.
27. Dallos T, Gálová LL, Macejková E, et al. Familial Mediterranean Fever – first experiences in Slovakia. *Vnitř Lék* 2014; 60: 80–85.
28. Dallos T, Ilenčíková D, Kovács L. Familial Mediterranean Fever – clinical picture, diagnosis and treatment. *Vnitř Lék* 2014; 60: 30–37.
29. Król P, Doležalová P. Recidivující febrilie u dětí. *Pediatr Praxi* 2013; 14: 221–224.
30. Sari I, Birlík M, Kasifoglu T. Familial Mediterranean Fever – An updated review. *Eur J Rheum* 2014; 1: 21–33.
31. Jeseňák M, Hrubíšková K, Kapustová L, et al. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region. *Bratisl Med J* 2018; 119: 198–200.
32. Drewe E, et al. Prospective study of anti-tumour necrosis factor superfamily 1 B fusion protein, and case study of anti-tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. *Rheumatology* 2003; 42: 235–239.
33. Nigrovic PA. Cryopyrin-Associated periodic syndromes and related disorders. www.uptodate.com, 2016
34. Majeed HA, Kalaawi M, Mohanty D, et al. Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. *J Pediatr* 1989; 115: 730–734.
35. Cheung MS, Theodoropoulou K, Lugin J, et al. Periodic Fever with Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome Is Associated with CARD8 Variant Unable To Bind the NLRP3 Inflammasome. *J Immunol* 2017; 198: 2063–2069.
36. Marshall GS, Edwards KM, Lawton AR PFAPA syndrome. *Pediatr Infect Dis J* 1989; 8: 658–659.
37. Thomas KT, Feder HM, Lawton AR, et al. Periodic fever syndrome in children. *J Pediatr* 1999; 135: 15–21.
38. Hofer M, Cochard M, Anton J, et al. PFAPA (periodic fever, oral aphthae, pharyngitis and cervical adenitis) syndrome: a new consensus on diagnostic criteria. *Ann Rheum Dis* 2009; 68 (Suppl. 3): 705.
39. Jeseňák M, Kapustová L, Škereňová M, et al. PFAPA syndróm a klinický imunológ. *Klinická imunológia a alergológia* 2016; 3: 11–15.
40. Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. *Ann Rheum Dis* 2015; 74: 799.
41. Cuisset L, Jeru I, Dumont B, et al. Mutation in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. *Ann Rheum Dis* 2011; 70: 495.
42. Toplak N, Doležalová P, Constantin T, et al. Periodic Fever syndromes in Eastern and Central European countries: result of a pediatric multinational survey. *Pediatric Rheumatology* 2010; 8: 29.
43. Toplak N, Frenkel J, Ozen S, et al. An international registry on autoinflammatory diseases: the Eurofever experience. *Ann Rheum Dis* 2012; 71: 1177–1182.
44. Shinar, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. *Ann Rheum Dis* 2012; 71: 1599–1605.